Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,010.31 -4.18 (-0.41%)
Official Closing Price Updated: 7:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Biotech Valuations Rise as New Clinical Platforms Show Progress
Via Investor Brand Network
News headline image
Biotech Valuations Rise as New Clinical Platforms Show Progress
From BioMedWire
Via GlobeNewswire
Eli Lilly Joins Tech Players In The $1T Market Capitalization Club ↗
The company’s GLP-1 drugs, Zepbound and Mounjaro, have driven investor appetite and pushed its share price by about 40% this year. 
Via Stocktwits
News headline image
Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps ↗
Eli Lilly fell while Biogen jumped. 
Via Investor's Business Daily
News headline image
Eli Lilly & Co (NYSE:LLY) Presents a Compelling Case for Growth at a Reasonable Price ↗
Eli Lilly (LLY) presents strong growth at a reasonable price (GARP), with accelerating earnings and revenue supported by top-tier profitability. 
Via Chartmill
News headline image
1 Spectacular Warren Buffett-Approved Index Fund That Could Turn $500 Per Month Into $1 Million ↗
Investing in an S&P 500 index fund can be a great way to build long-term wealth. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
Wall Street Rebounds—but Confidence Remains on a Short Leash ↗
After a bruising week, Wall Street regained its footing on Friday as rate-cut hopes resurfaced and fears around the AI sell-off eased, if only slightly. Solid PMI data and improving inflation... 
Via Chartmill
Topics Artificial Intelligence Economy
News headline image
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum ↗
Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures. 
Via Stocktwits
News headline image
Q3 Earnings Outperformers: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Merck (NYSE:MRK) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Billionaire Stanley Druckenmiller Dropped Nvidia, Palantir, and Eli Lilly Over the Past Year and Just Bought the 2 Cheapest Magnificent Seven Stocks. ↗
These Magnificent Seven players are well-positioned to benefit in the AI boom. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Top Dividend Stocks for Growth-Oriented Investors ↗
Who says you have to choose between the two? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant? ↗
The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back. 
Via The Motley Fool
Topics Government
News headline image
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? ↗
Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon. 
Via The Motley Fool
News headline image
3 Top Dividend Stocks to Buy in November ↗
November is a great month to be thankful for opportunities to invest in these fantastic companies. 
Via The Motley Fool
Topics Bonds Economy
News headline image
How To Play Eli Lilly Stock As It Hits A Much-Anticipated Milestone? ↗
Eli Lilly stock has already rallied 70% in less than four months. 
Via Talk Markets
News headline image
A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Eli Lilly Stock Just Joined the $1 Trillion Club. Should You Buy LLY Here?
Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will push meaningfully higher in 2026. 
Via Barchart.com
Topics Government
News headline image
Eli Lilly Breaks $1 Trillion Barrier, A First For The Healthcare Industry ↗
Eli Lilly hit a $1 trillion valuation for the first time, becoming the only healthcare company to reach the milestone as demand for its weight-loss drugs continues to surge. 
Via Talk Markets
News headline image
Eli Lilly Stock Is Rising Today: Here&#39;s What You Need To Know ↗
Eli Lilly and Co (NYSE:LLY) shares are trading higher on Friday. The company plans to start selling its obesity drug through a new approach aimed at expanding access. 
Via Benzinga
News headline image
The AI Valuation Conundrum: Is the Market Inflating a Bubble or Fueling a Revolution?
Concerns are mounting across financial markets regarding a potential "AI bubble," as sky-high valuations for technology companies, particularly those focused on artificial intelligence, trigger... 
Via TokenRing AI
Topics Artificial Intelligence Economy Fraud
News headline image
Eli Lilly Becomes First Pharma To Join $1 Trillion Club Alongside Nvidia, Apple, Others ↗
Eli Lilly became the first health care company to top $1 trillion in market capitalization on Friday. 
Via Investor's Business Daily
News headline image
Eli Lilly Stock Joins the $1 Trillion Club as LLY Hits New All-Time Highs
Eli Lilly (LLY) just became the first healthcare company to join the $1 trillion market cap club. Shares are trading at a new all-time high on Friday, Nov. 21. The stock is up 40% in the past year and... 
Via Barchart.com
News headline image
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Supernus Pharmaceuticals (NASDAQ:SUPN) and... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
What's Going On With Novo Nordisk Stock? ↗
The management team conducted a cost-cutting effort that is likely to result in a more efficient business. 
Via The Motley Fool
News headline image
KeyCorp Delivers Sobering Outlook for LifeMD, Slashing Price Target Amidst Operational Headwinds
KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a... 
Via MarketMinute
News headline image
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly? ↗
Novo Nordisk just addressed a problem that has prevented some from taking these drugs. 
Via The Motley Fool
News headline image
Correction and Clarification: Trifecta and Edward Fruitman, M.D., Do Not Maintain Any Contractual Relationship or Product Preference With Eli Lilly or LillyDirect®
November 20, 2025 -- The organization reiterates it has no partnership with Lilly and does not endorse or favor Eli Lilly products, including Zepbound®, in its weight-loss and medical services. 
Via 24-7 Press Release
News headline image
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗
Via MarketBeat
News headline image
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.